Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1)

Jingbo Xiao  1 , Catherine Z. Chen  1 , Zaohua Huang  2 , Irina U. Agoulnik  3 , Marc Ferrer  1 , Noel Southall  1 , Xin Hu  1 , Wei Zheng  1 , Alexander I. Agoulnik  2 , Juan J. Marugan  1
In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
[updated ].
Affiliations
Free Books & Documents
Review

Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1)

Jingbo Xiao et al.
Free Books & Documents

Excerpt

The peptide hormone relaxin has been clinically investigated as a beneficial treatment for acute heart failure (AHF). Relaxin has been shown to reduce blood pressure and promote vascular compliance in clinical studies, in addition to being able to remodel heart lesions. The target of relaxin’s action is the class A G-protein coupled receptor RXFP1. Here we present the discovery of the first small-molecule agonists of RXFP1 disclosed in the literature. Optimized compounds from this series are potent and highly selective RXFP1 agonists with similar efficacy as the natural hormone in functional assays. These molecules are easy to synthesize and the represented analog ML290 showed excellent in vitro absorption, distribution, metabolism, and excretion (ADME) data and in vivo pharmacokinetic (PK) properties. From our studies, we conclude that this probe, ML290, should be a very useful tool for the study of RXFP1 activation in pre-clinical disease models of heart failure and other diseases, and might provide a lead for the development of a small-molecule drug as an alternative to the current expensive recombinant human relaxin therapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Hisaw FL. Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med. 1926;23(8):661–663.
    1. Fevold HL, Hisaw FL, Meyer RK. The relaxative hormone of the corpus luteum. Its purification and concentration. J Am Chem Soc. 1930;52(8):3340–3348.
    1. Baylis C. Relaxin may be the “elusive” renal vasodilatory agent of normal pregnancy. Am J Kidney Dis. 1999;34:1142–4. discussion 1144–5. - PubMed
    1. Jeyabalan A, Shroff SG, Novak J, Conrad KP. In: The vascular actions of relaxin Relaxin and related peptides. Agoulnik AI, editor. Vol. 612. Springer; New York: 2007. pp. 65–87.
    1. Schrier RW, Durr JA. Pregnancy: an overfill or underfill state. Am J Kidney Dis. 1987;9:284–9. - PubMed

LinkOut - more resources